Patents by Inventor Jo Alen

Jo Alen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Further substituted triazolo quinoxaline derivatives
    Patent number: 11981677
    Abstract: The present invention relates to compounds according to general formula (I) which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.
    Type: Grant
    Filed: February 9, 2021
    Date of Patent: May 14, 2024
    Assignee: Grünenthal GmbH
    Inventors: Florian Jakob, Jo Alen, Simon Lucas, Tobias Craan, Ingo Konetzki, Achim Kless, Stefan Schunk, Paul Ratcliffe, Sebastian Wachten, Simon Cruwys
  • SUBSTITUTED PYRROLIDINE AMINES AND AMIDES VI
    Publication number: 20230265078
    Abstract: The invention relates to compounds according to general formula (I) which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.
    Type: Application
    Filed: July 9, 2021
    Publication date: August 24, 2023
    Applicant: Gruenenthal GmbH
    Inventors: Jo ALEN, Florian JAKOB, Sebastian KRUEGER, Philipp BARBIE
  • SUBSTITUTED PYRAZOLE AMIDES
    Publication number: 20230025025
    Abstract: The present invention relates to compounds according to general formula (I) which act as inhibitors of NaV1.8 and can be used in the treatment of pain.
    Type: Application
    Filed: June 15, 2022
    Publication date: January 26, 2023
    Applicant: GRUENENTHAL GMBH
    Inventors: Sebastian KRUEGER, Sebastian PEIL, Clemens DIALER, Marcel MUELBAIER, Markus WAGENER, Ingo KONETZKI, Nikolay SITNIKOV, Jo ALEN, Martin PETTERSSON
  • QUINOXALINE DERIVATIVES
    Publication number: 20220396578
    Abstract: The present invention relates to compounds according to general formula (I) which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.
    Type: Application
    Filed: July 18, 2022
    Publication date: December 15, 2022
    Applicant: GRUENENTHAL GMBH
    Inventors: Jo ALEN, Florian JAKOB, Sebastian KRUEGER, Daniela FRIEBE, Stephanie HENNEN
  • QUINOXALINE DERIVATIVES
    Publication number: 20220372041
    Abstract: The present invention relates to compounds according to general formula (I) which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.
    Type: Application
    Filed: July 18, 2022
    Publication date: November 24, 2022
    Applicant: GRUENENTHAL GMBH
    Inventors: Jo ALEN, Florian JAKOB, Sebastian KRUEGER, Philipp BARBIE, Daniela FRIEBE, Stephanie HENNEN
  • SUBSTITUTED PYRROLIDINE AMIDES II
    Publication number: 20220127264
    Abstract: The invention relates to compounds according to general formula (I), which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.
    Type: Application
    Filed: January 5, 2022
    Publication date: April 28, 2022
    Applicant: GRUENENTHAL GMBH
    Inventors: Florian JAKOB, Jo Alen, Sebastian Krueger, Markus Schade, Daniela Friebe, Stephanie Hennen
  • SUBSTITUTED PYRROLIDINE AMIDES V
    Publication number: 20220106294
    Abstract: The invention relates to compounds according to general formula (I), which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.
    Type: Application
    Filed: December 17, 2021
    Publication date: April 7, 2022
    Applicant: GRUENENTHAL GMBH
    Inventors: Florian JAKOB, Jo ALEN, Sebastian KRUEGER, Philipp BARBIE, Daniela FRIEBE
  • SUBSTITUTED PYRROLIDINE AMIDES IV
    Publication number: 20220106295
    Abstract: The invention relates to compounds according to general formula (I), which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.
    Type: Application
    Filed: December 17, 2021
    Publication date: April 7, 2022
    Applicant: GRUENENTHAL GMBH
    Inventors: Florian JAKOB, Jo ALEN, Sebastian KRUEGER, Daniela FRIEBE, Stephanie HENNEN
  • SUBSTITUTED PYRROLIDINE AMIDES III
    Publication number: 20220089573
    Abstract: The invention relates to compounds according to general formula (I), which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.
    Type: Application
    Filed: January 13, 2020
    Publication date: March 24, 2022
    Applicant: GRÜNENTHAL GMBH
    Inventors: Florian JAKOB, Jo ALEN, Sebastian KRÜGER, Daniela FRIEBE, Stephanie HENNEN, Philipp BARBIE
  • FURTHER SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES
    Publication number: 20210163491
    Abstract: The present invention relates to compounds according to general formula (I) which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.
    Type: Application
    Filed: February 9, 2021
    Publication date: June 3, 2021
    Applicant: Grünenthal GmbH
    Inventors: Florian JAKOB, Jo ALEN, Simon LUCAS, Tobias CRAAN, Ingo KONETZKI, Achim KLESS, Stefan SCHUNK, Paul RATCLIFFE, Sebastian WACHTEN, Simon CRUWYS
  • SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES
    Publication number: 20210139488
    Abstract: The present invention relates to compounds according to general formula (I) which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.
    Type: Application
    Filed: January 20, 2021
    Publication date: May 13, 2021
    Applicant: GRÜNETHAL GMBH
    Inventors: Florian JAKOB, Jo ALEN, Simon LUCAS, Tobias CRAAN, Ingo KONETZKI, Achim KLESS, Stefan SCHUNK, Paul RATCLIFFE, Sebastian WACHTEN, Simon CRUWYS
  • Further substituted triazolo quinoxaline derivatives
    Patent number: 10981918
    Abstract: The present invention relates to compounds according to general formula (I) which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.
    Type: Grant
    Filed: July 19, 2019
    Date of Patent: April 20, 2021
    Assignee: GRÜNENTHAL GMBH
    Inventors: Florian Jakob, Jo Alen, Simon Lucas, Tobias Craan, Ingo Konetzki, Achim Kless, Stefan Schunk, Paul Ratcliffe, Sebastian Wachten, Simon Cruwys
  • SUBSTITUTED PYRROLIDINE AMIDES III
    Publication number: 20200223840
    Abstract: The invention relates to compounds according to general formula (I), which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.
    Type: Application
    Filed: January 13, 2020
    Publication date: July 16, 2020
    Applicant: GRUENENTHAL GMBH
    Inventors: Florian JAKOB, Jo ALEN, Sebastian KRÜGER, Daniela FRIEBE, Stephanie HENNEN, Philipp BARBIE
  • Substituted pyrrolidine amides I
    Patent number: 10626106
    Abstract: The invention relates to compounds according to general formula (I), which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: April 21, 2020
    Assignee: GRUENENTHAL GMBH
    Inventors: Florian Jakob, Jo Alen, Sebastian Krüger, Markus Schade, Daniela Friebe, Stephanie Hennen
  • FURTHER SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES
    Publication number: 20200024281
    Abstract: The present invention relates to compounds according to general formula (I) which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.
    Type: Application
    Filed: July 19, 2019
    Publication date: January 23, 2020
    Applicant: Grünenthal GmbH
    Inventors: Florian JAKOB, Jo ALEN, Simon LUCAS, Tobias CRAAN, Ingo KONETZKI, Achim KLESS, Stefan SCHUNK, Paul RATCLIFFE, Sebastian WACHTEN, Simon CRUWYS
  • Substituted Pyrrolidine Amides II
    Publication number: 20190185470
    Abstract: The invention relates to compounds according to general formula (I), which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.
    Type: Application
    Filed: December 18, 2018
    Publication date: June 20, 2019
    Inventors: Florian JAKOB, Jo ALEN, Sebastian KRÜGER, Markus SCHADE, Daniela FRIEBE, Stephanie HENNEN
  • Substituted Pyrrolidine Amides I
    Publication number: 20190185455
    Abstract: The invention relates to compounds according to general formula (I), which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.
    Type: Application
    Filed: December 18, 2018
    Publication date: June 20, 2019
    Inventors: Florian JAKOB, Jo ALEN, Sebastian KRÜGER, Markus SCHADE, Daniela FRIEBE, Stephanie HENNEN
  • Soft rock inhibitors
    Patent number: 9174939
    Abstract: The present invention relates to new kinase inhibitors, more specifically ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In particular, the present invention relates to new ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In addition, the invention relates to methods of treatment and use of said compounds in the manufacture of a medicament for the application to a number of therapeutic indications including sexual dysfunction, inflammatory diseases, ophthalmic diseases and Respiratory diseases.
    Type: Grant
    Filed: August 31, 2012
    Date of Patent: November 3, 2015
    Assignee: Amakem NV
    Inventors: Jo Alen, Sandro Boland, Arnaud Pierre Jean Bourin, Olivier Defert, Dirk Leysen
  • Rock kinase inhibitors
    Patent number: 9079858
    Abstract: The present invention relates to new kinase inhibitors, more specifically ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In particular, the present invention relates to new ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In addition, the invention relates to methods of treatment and use of said compounds in the manufacture of a medicament for the application to a number of therapeutic indications including sexual dysfunction, inflammatory diseases, ophthalmic diseases and respiratory diseases.
    Type: Grant
    Filed: August 31, 2012
    Date of Patent: July 14, 2015
    Assignee: Amakem NV
    Inventors: Jo Alen, Sandro Boland, Arnaud Pierre Jean Bourin, Olivier Defert, Dirk Leysen
  • Rock inhibitors
    Patent number: 9073905
    Abstract: The present invention relates to new kinase inhibitors of Formula (I), wherein X is oxygen, —NH—, or a direct bond; Y is —NH— or a direct bond; n is an integer from 0 to 4; m is an integer from 0 to 4; Cy represents a bivalent radical consisting of a satured (poly)cycle, including fused, bi-, spiro or bridged carbocycles and heterocycles; in particular selected from the group consisting of: Formula (II), Ar is selected from the group comprising: Formula (III), R2 is hydrogen or methyl; R8 is hydrogen, methyl, halogen, or alkynyl; R1 is an aryl or heteroaryl more specifically ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In particular, the present invention relates to new ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: July 7, 2015
    Assignee: Amakem NV
    Inventors: Dirk Leysen, Olivier Defert, Sandro Boland, Jo Alen, Arnaud Pierre Jean Bourin